The objective was to investigate the cellular effect and action mechanism of Artemisia capillaris extract (ACE) and its component, scopoletin, on penile corpus cavernosum smooth muscle (PCCSM). In vitro study with PCCSM, the precontracted PCCSM with phenylephrine was treated with ACE or scopoletin. Cyclic nucleotides in the perfusate were measured by radioimmunoassay and expression of protein and mRNA of endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase in the perfused PCCSM were measured by western blot and real-time PCR, respectively. The interaction of ACE or scopoletin with udenafil was also evaluated. ACE and scopoletin exerted a significant and concentration-dependent relaxation in PCCSM. The perfusion with ACE or scopoletin significantly increased cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) and the perfusion with ACE or scopoletin increased the expression of eNOS mRNA and protein. Furthermore, ACE or scopoletin enhanced udenafil-inducing relaxation in PCCSM. ACE and scopoletin relaxed the PCCSM mainly by activating nitric oxide-cGMP system and cAMP pathway and they may be additive therapeutic candidates for ED patients who do not completely respond to udenafil.
INTRODUCTION
ED is defined as the consistent or recurrent inability to attain and/ or maintain an erection to permit satisfactory sexual intercourse. 1, 2 According to the 2003-2004 National Health and Nutrition Examination Survey (NHANES), the overall prevalence of ED in men ⩾ 20 years of age was approximately 17 million in the United States. 3 Normal penile erection is dependent upon nitric oxide (NO) and its enzyme nitric oxide synthase (NOS). Upon penile erection, release of NO from nitrergic nerve and endothelial cells activates guanylyl cyclase resulting in increase of cyclic guanosine monophosphate (cGMP) formation, which mediates cavernosum smooth muscle relaxation. 4, 5 Adenyl cyclase is also an important stimulator on the production of cyclic adenosine monophosphate (cAMP), which will act in ion channel, leading to relaxation of penile corpus cavernosum. [6] [7] [8] Natural products provide a valuable and rich pool for the discovery of drug candidates. Many researchers are trying to discover valuable therapeutic agents from natural sources, as the newly created chemical compound libraries had limited structural diversity in the area of pharmaceutical therapeutics. 9 Artemisia capillaris Thunb (A. capillaris) is a traditional herbal medicine for liver cirrhosis, liver cancer, jaundice and cholecystitis in Asian countries. [10] [11] [12] Many studies have demonstrated the effect of free radical scavenging, antimicrobial activities, anticarcinogenicity 13, 14 and dilation of blood vessel. [15] [16] [17] [18] Recently, it has been also shown that the extract from Artemisia species had the vasorelaxing activity on thoracic aorta in rat through the endothelial NOS (eNOS)/cGMP pathway. 19, 20 The penis is a vascular organ and has similar physical characteristics in vascular smooth muscle. 21 Several compounds have been isolated form A. capillaris, including coumarin derivatives such as 6,7-dimethylesculetin, esculetin and scopoletin. 22 Scopoletin (7-hydroxy-6-methoxy-2H-1-benzopyran-2-one) is one of the active components of A. capillaris used as 7-hydroxyl group that demonstrated antioxidant activities 23 and anti-inflammatory activity in vivo. 24 The objective of this study was to clarify the relaxation effects and mechanism of A. capillaris extract (ACE) or scopoletin on penile corpus cavernosum smooth muscle (PCCSM). The study also investigated the additional effects of ACE or scopoletin on udenafil-induced PCCSM relaxation. The study also investigated a possibility for the supplement of ACE or scopoletin to develop the effective combination with udenafil for ED patients who did not strongly respond to udenafil only.
Activity-guided isolation
The shade-dried A. capillaris (2.5 kg) were pulverized and extracted three times with ethanol for 3 h using an ultrasonic bath (model 8510 DHT; Branson, CT, USA). The ethanol extract (98.55 g) was partitioned with n-hexane, ethyl acetate and n-butanol in succession. Active ethyl acetate fraction (35.03 g) was chromatographed on silica gel using a gradient dichloromethane-ethyl acetate system to yield 24 fractions. Among these fractions, fraction 13 (1.08 g) showed relaxation effects and scopoletin was identified as active principle by more purification on Sephadex LH-20 with methanol elution. The chemical structure of scopoletin was determined by 1 H, 13 C NMR and ESI-MS spectroscopic data (Figure 1 ). 
Chemicals and reagents

Tissue preparation
All animal procedures for this study were performed in accordance with the regulations of the care and use of laboratory animals guide, which were approved by the Institutional Animal Care and Use Committee of Chonbuk National University Laboratory Animal Center (IACUC, CBU 2012-0051, CBU 2012-0052), and all efforts were made to minimize animal suffering.
The healthy male New Zealand white rabbits (2.5-3.0 kg) were housed in a controlled environment, one in each cage, at 18 ± 1°C and under relative humidity 62 ± 5%. These rabbits were acclimated in such an environment for the first week. The animals were randomly allocated into the experiment, respectively. The rabbits were intravenously anesthetized with 50 mg kg -1 ketamine plus 25 mg kg − 1 rumpun (xylazine hydrochloride) (Bayer, Ansan, Korea) and exsanguinated. After acclimatization, the animals were randomized allocated into the experiment, respectively. The penis was excised rapidly. For ex vivo penile perfusion model, penis was prepared as described previously. 25 The chamber for penile perfusion had a hole at the bottom to allow collection of the perfusate. The penis was perfused with ACE or scopoletin for 2 h, to measure cAMP and cGMP concentration in the perfusate. Another sample of penis was perfused with ACE or scopoletin for 2 h for evaluation of quantitative real-time PCR analysis and western blot for eNOS and neuronal NOS (nNOS) expression.
Measurement of tension on PCCSM
Preparation of penile strip chamber model. The PCCSM was then carefully dissected free from the surrounding tunica albuginea. Strip of PCCSM (1.5 × 1.5 × 7 mm) was vertically placed in a 2 ml organ chamber with one end connected with a thread to the prong of a force transducer (FT03, Grass Telefactor; West Warwick, RI, USA), and the other end secured with a thread to a holder for isometric tension measurement. The organ chamber containing a HEPES buffer (36°C) was constantly aerated with 100% O 2 . After mounting, the strip was equilibrated for 60 min with several adjustments of length until a baseline force stabilized at 1 g, and the oxygenated buffer was replaced every 15 min. After stabilization, 10 μM Phe was added to adjust the maximal contractile tension, and then the samples were added to the organ chamber with the desired final concentration. ACE (0.1, 0.5, 1 and 2 mg ml -1 ) was added to the perfusion medium in sequence, each for 10 min. Scopoletin was tested at concentrations 0.1, 1, 10 and 100 μM. The PCCSM was preincubated with L-NAME (1 mM) for 30 min to block NOS, preincubated with ODQ (10 μM) for 30 min to block guanylate cyclase, preincubated with MDL 12330 A (10 μM) for 30 min to block adenylyl cyclase or preincubated with H-89 (100 μM) for 30 min to block protein kinase A (PKA) were also performed.
Interaction of ACE or scopoletin with udenafil and rolipram in PCCSM tension. The strip of PCCSM was preincubated with udenafil (0.1 μM) or rolipram (1 μM) for 30 min, then ACE (1 mg ml − 1 ) or scopoletin (10 μM) was added to the organ chamber after Phe-induced contraction. Inversely, the penile tissue preincubated with ACE or scopoletin was also added with udenafil or rolipram after Phe-induced contraction.
Real-time PCR analysis for eNOS and nNOS mRNA
Total RNA was extracted from PCCSM dissected from ex vivo penis using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription was performed using Superscript II and 18-mers Oligo-dT (Takara Bio, Kyoto, Japan). The primer sequences were as follows: rabbit nNOS 5′-GAGAA-GCAACGCCTGTTGGT-3′ (forward) and 5′-CCCCAT TTCCACTCCTCGTA-3′ (reverse), rabbit eNOS 5′-TCGTCCCTGTGGAAAGACAAG-3′ (forward) and 5′-CTTTGGCGAGCTGGTAACTGT-3′ (reverse). PCR reaction was carried out in 384-well plates using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA). All reactions were done in triplicate.
Western blot for eNOS and nNOS expression
The PCCSM dissected from ex vivo penis, which was perfused with ACE or scopoletin, was homogenized in ice-cold buffer. The homogenized solution was placed on ice for 15 min and centrifuged at 4°C. The supernatant was separated. Quantitative protein (20 μg) was denatured at 95°C for 5 min and electrophoresis was done on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. eNOS and nNOS (BD Biosciences, Franklin Lakes, NJ, USA; cat: 610298, 610311) antibodies were reacted for 2 h and the membrane was washed three times using Tween tris buffered saline at 10-min intervals. As secondary antibodies, goat anti-rabbit immunoglobulin G-horseradish peroxidase for eNOS and nNOS (Zymed Laboratories, San Francisco, CA, USA; cat: G-21234) were reacted at room temperature, and the membrane was washed again with Tween tris buffered saline six times with 5-min interval between each washing. Chemiluminescence was detected using ECL western blot detection reagents. Beta-actin was used for the control.
Radioimmunoassay of cAMP and cGMP concentration
For the measurement of cAMP and cGMP concentration in the perfusate, 100 μl of the perfusate was treated with 300 μl trichloroacetic acid to final concentration of 6% for 15 min at room temperature, and centrifuged at 4°C. The supernatant (100 μl) was extracted three times with water-saturated ether, and then dried using a SpeedVac concentrator (Savant, Farmingdale, NY, USA). The pellets were resuspended with ether and then dried. The pellet was treated with 500 μl NaOH (1 N), ultrasonicated and used for protein determination. Levels of cAMP and cGMP were measured with a specific radioimmunoassay, as described previously. 26 
Statistical analysis
The submaximal penile contractile responses induced by Phe were considered to be 100%, and all subsequent responses to ACE or scopoletin were expressed as a percentage of this value. The results were expressed as mean ± s.d., and n represents the number of PCCSM in each group. The statistical significance of differences was calculated by one-way analysis of variance, followed by Bonferroni's multiple comparison test. Concentration-dependent responses before and after the treatment with blockers were compared using Student's paired t-test. A probability value o0.05 was considered significant.
RESULTS
Cumulative effects of ACE or scopoletin in PCCSM ACE demonstrated a significant and concentration-dependent relaxation effect ( Figure 2 ). The application of ACE on L-NAME (EC50 value: 2.64 ± 0.19 mg ml -1 ; Figure 2a ), ODQ (EC50 value: 2.54 ± 0.06 mg ml − 1 ; Figure 2b ), MDL 12330 A (EC50 value: 2.00 ± 0.03 mg ml -1 ; Figure 2c ) or H-89 (EC50 value: 2.37 ± 0.10 mg ml − 1 ; Figure 2d ) pretreated PCCSM decreased the relaxations induced by ACE. L-NAME, ODQ, MDL 12330 A and H-89 significantly blocked the ACE-induced relaxation at 1 mg ml − 1 (P o 0.05) and 2 mg ml − 1 (P o 0.01), respectively ( Table 1) .
Scopoletin exerted a significant and concentration-dependent relaxation ( Figure 2 ). The relaxations induced by scopoletin on L-NAME (EC50 value: 2.66 ± 0.13 μM; Figure 2e ), ODQ (EC50 value: 2.08 ± 0.38 μM; Figure 2f ), MDL 12330 A (EC50 value: 2.60 ± 0.20 μM; Figure 2g ) or H-89 (EC50 value: 2.54 ± 0.28 μM; Figure 2h ) pretreated PCCSM were significantly inhibited ( Figure 2 ). L-NAME and ODQ significantly inhibited the scopoletin-induced relaxation (P o 0.01), respectively. MDL 12330 A and H-89 significantly blocked the scopoletin-induced relaxation at 100 μM (Po 0.01), respectively (Figures 2g and h; Table 1 ).
ACE or scopoletin in PCCSM preincubated with udenafil
The relaxation value induced by a single dose of udenafil on Phe precontracted PCCSM was 12.02 ± 1.41% (Figure 3a ). On the other hand, ACE-induced relaxation on Phe precontracted PCCSM was 19.85 ± 1.17%. The combined relaxation value of udenafil and ACE was 30.71 ± 1.72% on udenafil preincubated PCCSM and 22.68 ± 1.35% on the ACE preincubated PCCSM, respectively. ACE significantly enhanced the udenafil-induced relaxation more than threefold (P o0.01; Figure 3b ). Rolipram also induced relaxation dose dependently (0.01-10 μM) on Phe precontracted PCCSM (Figure 3d ). ACE preincubation efficiently improved the rolipram-induced relaxation more than twofold (P o 0.01; Figure 3e ). In addition, rolipram preincubation strongly improved the ACE-induced relaxation (Figure 3c ).
The relaxation value induced by a single dose of udenafil on Phe precontracted PCCSM was 9.24 ± 1.30%. On the other hand, scopoletin-induced relaxation of 11.04 ± 1.35% on Phe precontracted PCCSM. The combined relaxation value of udenafil and scopoletin was 18.12 ± 1.66% on udenafil preincubated PCCSM and 17.22 ± 2.74% on scopoletin preincubated PCCSM, respectively. The scopoletin preincubation efficiently improved the udenafil-induced relaxation more than twofold (P o 0.01) although it had less potency than ACE (Figure 3c ). Scopoletin preincubation also significantly enhanced the rolipram-induced relaxation more than twofold (P o0.01; Figure 3f ).
The expression of eNOS and nNOS mRNA in PCCSM The eNOS and nNOS mRNA levels are depicted in Figure 4 . Results showed that eNOS mRNA level was significantly increased by ACE or scopoletin more than twofold (P o 0.01). Pretreatment with L-NAME or ODQ on PCCSM significantly decreased the eNOS mRNA level, which was increased by ACE or scopoletin (Po 0.01). On the other hand, nNOS mRNA level was not enhanced by ACE or scopoletin. However, pretreatment with L-NAME or ODQ on PCCSM significantly decreased the nNOS mRNA level induced by ACE (P o 0.05) or scopoletin (Po 0.01).
The expression of eNOS and nNOS in PCCSM
The eNOS level was significantly increased by ACE or scopoletin (P o 0.01; Figure 5 ). Pretreatment with L-NAME or ODQ on PCCSM significantly decreased the expression of eNOS, which was increased by ACE (P o 0.01) or scopoletin (P o 0.05). On the other hand, nNOS level was not significantly enhanced by ACE or scopoletin. However, pretreatment with L-NAME or ODQ on PCCSM slightly decreased the expression of nNOS induced by ACE or scopoletin (P o 0.05).
ACE or scopoletin on cAMP/cGMP in perfusate
Both cAMP and cGMP were significantly increased by ACE or scopoletin in the perfusate ( Table 2 ). The highest yield of cAMP and cGMP in perfusate was at 2 mg ml − 1 with ACE. The yields of cAMP and cGMP were increased in a concentration-dependent manner with a maximum value of 1861.18 ± 61.34 fmol ml − 1 and 359.05 ± 29.18 fmol ml − 1 , respectively. The effect of scopoletin was the most potent at 100 μM and the maximum value of cAMP and cGMP was 1609.50 ± 68.89 fmol ml -1 and 338.50 ± 21.09fmol ml − 1 , respectively.
DISCUSSION
Normal penile erection depends on the relaxation of PCCSM. 27 The relaxation of PCCSMs are regulated by NO-induced elevation of cellular cGMP. 28 Binding of cGMP to cGMP-dependent protein kinases or cGMP-dependent ion channels results in reduction of intracellular calcium.
This causes diminution of smooth muscle contractility and enhances penile erection. 29 In addition, cAMP was found to be important as an intracellular second messenger. 30 Adenylyl cyclase causes an increase in the intracellular concentration of cAMP, which binds to cAMP-dependent protein kinase, PKA. 31 This decreased the intracellular calcium level leading to the relaxation of PCCSM. 32 This study showed that ACE or scopoletin had a significant relaxation effect in a concentration-dependent manner on PCCSM (Figure 2 ). ACE or scopoletin also increased the cAMP and cGMP levels in the perfusate ( Table 2 ). These results suggest that ACE or scopoletin may have a good effect on erectile function and possibly be involved in NO-cGMP and adenylyl cAMP-PKA signaling pathways. Furthermore, capillarisin and 6,7-dimethylesculetin isolated from ACE also showed a significant relaxation effect in a concentration-dependent manner on PCCSM at the same range of 0.1-100 μM. 33, 34 Therefore, it seems worthy to continue the research about the structure-activity relationship of components from ACE.
The primary intracellular activation pathway for cavernous smooth muscle relaxation appears to be mediated through the NO-cGMP signal pathway, and the cAMP system apparently functions as a secondary pathway. 35, 36 We hypothesized that ACE or scopoletin-induced relaxation would be inhibited after treatment with L-NAME and ODQ, if activation of NO-cGMP pathway was involved in the signal pathway. ACE and scopoletin-induced relaxation also would be blocked with MDL 12330 A or H-89, if activation of adenylyl cyclase cAMP-PKA pathway was involved in the signal pathway. Our results confirmed both the theories in PCCSM.
The NO involved in penile erection is produced by an enzyme NOS and is known to be an important bioactive substance involved in various physiological and pathophysiological processes. 37 The NO generated by eNOS and nNOS in the penile tissue generates penile erection and sustains an erected penis, respectively. 38 Released NO activates soluble guanylate cyclase and increases the production of cGMP. 39 Through a protein kinase cascade, hyperpolarization and intracellular calcium sequestration, cavernous smooth muscle relaxation and arteriolar vasodilation occur. 40 In this study, eNOS mRNA and eNOS protein levels were significantly increased in PCCSM when incubated with ACE or scopoletin for 2 h. This study showed that L-NAME, ODQ, MDL 12330 A and H-89 significantly inhibited ACE or scopoletin-induced relaxation as presented in Figure 2 . Those results suggest ACE or scopoletin may have an effect related to the NO-cGMP and adenylyl cAMP-PKA pathway and help maintaining erection.
Although many drugs have been used to treat ED, finding a new drug or an alternative medicine to treat ED and understanding its mechanism of action is still meaningful research field. Current pharmacological treatment for ED includes the oral and intracavernosal, administration routes of medicines. 41, 42 Oral PDE5 is such as avanafil, mirodenafil, sildenafil, tadalafil, udenafil and vardenafil have been commonly used for the treatment of ED patients. These oral medications are proven to be valuable in the management of ED, but are reported to have limitations. 4, 43 There are difficulties in the development of a new chemical medicine with complete efficacy as well. Therefore, we are focusing on finding a new herbal medicine or a supplement from the natural products, especially herbal medicine. Many patients want to use alternative medicine from natural products to improve the ED as well. In addition, ACE and scopoletin enhanced udenafil-induced relaxation and may improve ED in patients who do not completely respond to udenafil.
In conclusion, ACE and scopoletin, which is the active component from A. capillaris, significantly relaxed PCCSM and showed an increasing effect on udenafil-induced relaxation. The increased cAMP and cGMP levels in perfusate, the increased expression of eNOS and the inhibition of ACE or scopoletin relaxation with L-NAME, ODQ, MDL 12330 A and H-89 suggested ACE or scopoletin may be involved in penile erection through the NO-cGMP and adenylyl cAMP-PKA signaling pathways. ACE or scopoletin may be a good candidate of new additive medicine or a supplement for the patients who want to use natural products to improve erectile function. The combination of ACE or scopoletin with udenafil may be helpful for the patients, who are not satisfied with udenafil leading to incomplete erection.
